Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer
The individualization of cancer treatment has brought about revolution in clinical practice. In recent years, EGFR-TKI has shown good anti-tumor activity in non-small cell lung cancer with EGFR positive mutation. Compared with the first-generation EGFR-TKI, the third-generation EGFR-TKI significantl...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Magazine House of Cancer Research on Prevention and Treatment
2021-12-01
|
| Series: | Zhongliu Fangzhi Yanjiu |
| Subjects: | |
| Online Access: | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2021.21.0761 |
| _version_ | 1828145968018620416 |
|---|---|
| author | XU Wenwen ZHU Yuxi |
| author_facet | XU Wenwen ZHU Yuxi |
| author_sort | XU Wenwen |
| collection | DOAJ |
| description | The individualization of cancer treatment has brought about revolution in clinical practice. In recent years, EGFR-TKI has shown good anti-tumor activity in non-small cell lung cancer with EGFR positive mutation. Compared with the first-generation EGFR-TKI, the third-generation EGFR-TKI significantly increased the effective rate, progression-free survival and overall survival of advanced non-small cell lung cancer with EGFR mutation, especially the brain metastases. And the third-generation EGFR-TKI also showed the benefits of disease-free survival as the post-operative adjuvant therapy for operable EGFR-mutated non-small cell lung cancer. Moreover, the third-generation EGFR-TKI in combination with radiotherapy showed obvious advantages in the treatment of locally advanced and advanced oligometastatic EGFR-mutated non-small cell lung cancer. |
| first_indexed | 2024-04-11T20:41:11Z |
| format | Article |
| id | doaj.art-f3eba82cdf8d4158af4d0390f2ebf03a |
| institution | Directory Open Access Journal |
| issn | 1000-8578 |
| language | zho |
| last_indexed | 2024-04-11T20:41:11Z |
| publishDate | 2021-12-01 |
| publisher | Magazine House of Cancer Research on Prevention and Treatment |
| record_format | Article |
| series | Zhongliu Fangzhi Yanjiu |
| spelling | doaj.art-f3eba82cdf8d4158af4d0390f2ebf03a2022-12-22T04:04:13ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782021-12-0148121129113410.3971/j.issn.1000-8578.2021.21.07618578.2021.21.0761Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung CancerXU Wenwen0ZHU Yuxi1Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, ChinaDepartment of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400042, ChinaThe individualization of cancer treatment has brought about revolution in clinical practice. In recent years, EGFR-TKI has shown good anti-tumor activity in non-small cell lung cancer with EGFR positive mutation. Compared with the first-generation EGFR-TKI, the third-generation EGFR-TKI significantly increased the effective rate, progression-free survival and overall survival of advanced non-small cell lung cancer with EGFR mutation, especially the brain metastases. And the third-generation EGFR-TKI also showed the benefits of disease-free survival as the post-operative adjuvant therapy for operable EGFR-mutated non-small cell lung cancer. Moreover, the third-generation EGFR-TKI in combination with radiotherapy showed obvious advantages in the treatment of locally advanced and advanced oligometastatic EGFR-mutated non-small cell lung cancer.http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2021.21.0761osimertinibalmonertinibfurmonertinibegfr mutationnon-small cell lung cancer |
| spellingShingle | XU Wenwen ZHU Yuxi Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer Zhongliu Fangzhi Yanjiu osimertinib almonertinib furmonertinib egfr mutation non-small cell lung cancer |
| title | Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer |
| title_full | Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer |
| title_fullStr | Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer |
| title_full_unstemmed | Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer |
| title_short | Application of Third-generation TKIs in EGFR-mutated Non-small Cell Lung Cancer |
| title_sort | application of third generation tkis in egfr mutated non small cell lung cancer |
| topic | osimertinib almonertinib furmonertinib egfr mutation non-small cell lung cancer |
| url | http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2021.21.0761 |
| work_keys_str_mv | AT xuwenwen applicationofthirdgenerationtkisinegfrmutatednonsmallcelllungcancer AT zhuyuxi applicationofthirdgenerationtkisinegfrmutatednonsmallcelllungcancer |